LifeMap Solutions Appoints Robert W. Peabody Chief Financial Officer
SAN JOSE, Calif. – Nov 24, 2015 – LifeMap Solutions, a subsidiary of BioTime, Inc., today announced the appointment of Robert W. Peabody as Chief Financial Officer. LifeMap is a technology pioneer, and an emerging provider of digital mobile health products, including ResearchKit and HealthKit apps, in collaboration with the Icahn School of Medicine at Mount Sinai. Mr. Peabody brings over 30 years of early stage company experience to LifeMap Solutions.
“Bob’s proven leadership and financial skills would enhance any company, and his deep knowledge of our company’s vision and opportunities makes him even more valuable to us,” said Corey Bridges, LifeMap Solutions CEO. “His background at Ernst & Young and his early-stage company experience will act as a significant accelerant as we grow our business.”
Since 2007, Peabody has helped LifeMap Solutions’ parent company, BioTime, Inc., acquire and develop a diverse portfolio of companies in the fields of regenerative medicine, diagnostics, and internet based genetic research. “Bob has a substantial track record and has played an instrumental role in developing past early-stage companies, having participated in the founding of Geron Corporation, Ocata Therapeutics, Inc. and Asterias Therapeutics, Inc.,” said Michael D. West, Ph.D., co-CEO of BioTime. “In this new role, Bob is expected to help guide LifeMap Solutions through its critical early stage, capitalizing on the great momentum that the company is currently enjoying.”
About LifeMap Solutions, Inc.
LifeMap Solutions is developing innovative digital health solutions in partnership with the Icahn Institute for Genomics and Multiscale Biology, which is located within the Icahn School of Medicine at Mount Sinai. LifeMap Solutions integrates health and wellness information with care team guidance into a secure mHealth platform to deliver digital health solutions that empower patients to make better choices to achieve optimal health outcomes. LifeMap Solutions is a subsidiary of BioTime, Inc. LifeMap Solutions is headquartered in San Jose, California. For more information, please visit www.lifemap-solutions.com.
About BioTime, Inc.
BioTime, Inc., a pioneer in regenerative medicine, is a clinical-stage biotechnology company. BioTime and its subsidiaries are leveraging their industry-leading experience in pluripotent stem cell technology and a broad intellectual property portfolio to facilitate the development and use of cell-based therapies and gene marker-based molecular diagnostics for major diseases and degenerative conditions for which there presently are no cures. The lead clinical programs of BioTime and its subsidiaries include: OpRegen®, currently in a Phase I/IIa trial for the treatment of the dry form of age-related macular degeneration; AST-OPC1, currently in a Phase I/IIa trial for spinal cord injuries; Renevia™, currently in a pivotal trial in Europe as an injectable matrix for the engraftment of transplanted cells to treat HIV- related lipoatrophy; and PanC-Dx™ cancer diagnostics, which are completing clinical studies for bladder, breast, and lung cancer. AST-VAC2, a cancer vaccine, is in the pre-clinical trial stage.
BioTime’s subsidiaries include: publicly-traded Asterias Biotherapeutics, Inc. (NYSE MKT: AST), developing pluripotent stem cell-based therapies in neurology and oncology, including AST-OPC1 and AST-VAC2 ; Cell Cure Neurosciences Ltd., developing stem cell-based therapies for retinal and neurological disorders, including OpRegen®; OncoCyte Corporation, developing PanC-Dx™ cancer diagnostics; LifeMap Sciences, Inc., developing and marketing an integrated on-line data base resource for biomedical and stem cell research; LifeMap Solutions, Inc., a subsidiary of LifeMap Sciences, developing mobile health (mHealth) products; ES Cell International, Pte Ltd., which has developed cGMP compliant human embryonic stem cell lines that are being marketed by BioTime for research purposes under the ESI BIO branding program; OrthoCyte Corporation, developing therapies to treat orthopedic disorders, diseases and injuries; and ReCyte Therapeutics, Inc., developing therapies to treat a variety of cardiovascular and related ischemic disorders.